Table 1 Patient characteristics at baseline
| Â | Etanercept | Tocilizumab 1. Biologic | Tocilizumab switcher | IL-1 inhibitors (anakinra or Canakinumab) 1. Biologic | IL-1 inhibitors (anakinra or canakinumab) switcher |
|---|---|---|---|---|---|
Patient numbers | 143 | 37 | 34 | 17 | 43 (30 + 13) |
Gender (female) | 72 (50.3%) | 20 (54%) | 17 (50%) | 6 (35%) | 22 (52%) |
Age at onset (years) | |||||
 mean +/-SD | 5.0 +/- 3.8 | 5.8 +/- 4.3 | 3.7 +/- 3.4 | 6.8 +/- 4.7 | 4.5 +/- 3.2 |
 median (IQR) | 4.1 (2.3; 6.4) | 4.9 (2.2; 8.1) | 2.6 (1.4; 4.4) | 5.2 (3.5; 11.2) | 3.7 (247; 5.3) |
Age at bDMARD start (years) | |||||
 mean +/- SD | 9.4 +/- 5.0 | 7.8 +/- 4.9 | 10.7 +/- 4.4 | 9.2 +/- 4.8 | 9.6 +/- 4.6 |
 median (IQR) | 8.2 (5.3; 13.0) | 7.2 (3.2; 12.0) | 10.6 (8.3; 13.7) | 8.1 (5.1; 13.3) | 8.4 (5.7; 13.2) |
Disease duration (years) | |||||
 mean +/- SD | 4.5 +/- 4.1 | 2.0 +/- 2.6 | 7.0 +/- 4.3 | 4.1 +/- 4.0 | 5.1 +/- 3.9 |
 median (IQR) | 3.3 (1.1; 6.6)) | 0.8 (0.3; 2.5) | 7.4 (3.6; 9.8) | 2.8 (0.6; 7.0) | 5.2 (1.5; 8.7) |
Pretreatment oral | |||||
 steroids | 143 (100%) | 37 (100%) | 34 (100%) | 11 (65%) | 41 (95%) |
 steroid pulse therapy | 24 (16.8%) | 10 (27%) | 6 (18%) | 5 (29%) | 12 (28%) |
 i.a. steroids | 42 (29.4%) | 4 (11%) | 7 (21%) | 0 | 10 (23%) |
 MTX | 126 (88.1%) | 29 (78%) | 31 (91%) | 8 (47%) | 36 (83%) |
 other DMARDs | 136 (95.1%) | 6 (16%) | 12 (35%) | 3 (18%) | 20 (47%) |
 biologics | 2 (1.4%) | 0 | 34 (100%) | 0 | 39 (65.0%) |
 abatacept | 0 | 0 | 1 (3%) | 0 | 0 |
 adalimumab | 0 | 0 | 3 (9%) | 0 | 3 (5.0%) |
 anakinra | 2 (1.4%) | 0 | 18 (53%) | 0 | n.a |
 canakinumab | 0 | 0 | 2 (6%) | 0 | n.a. |
 etanercept | 0 | 0 | 27 (79%) | 0 | 32 (74.0%) |
 infliximab | 0 | 0 | 1 (3%) | 0 | 0 |
 tocilizimab | 0 | 0 | 0 | 0 | 9 (21%) |
Concomitant treatment at enrolment | |||||
 steroids | 118 (82.5%) | 19 (51%) | 12 (34%) | 8 (47%) | 19 (44%) |
 MTX | 116 (81.1%) | 25 (68%) | 21 (62%) | 5 (29%) | 18 (42%) |
 other DMARDs | 34 (23.8%) | 3 (8%) | 3 (9%) | 2 (12%) | 4 (10%) |
Systemic manifestations at enrolment | |||||
 fever | 1/13 (7.7%) | 16/30 (53%) | 7/32 (22%) | 7/14 (50%) | 5/16 (31%) |
 exanthema | 2/13 (15.4%) | 11/30 (37%) | 7/32 (22%) | 8/15 (53%) | 2/16 (13%) |
 hepatomegaly | 0/2 (0%) | 9/20 (45%) | 2/14 (14%) | 1/9 (11%) | 1/7 (14%) |
 splenomegaly | 0/13 (0%) | 7/30 (23%) | 3/32 (9%) | 2/15 (13%) | 2/16 (13%) |
 serositis | 0/13 (0%) | 5/29 (17%) | 1/31 (3%) | 1/15 (7%) | 1/16 (6%) |
 any systemic manifestation | 2 (1.4%) | 21/31 (68%) | 9/34 (27%) | 9/15 (60%) | 7/16 (44%) |
Disease activity joints | |||||
 swollen | 114 (79.7%) | 21 (57%) | 21 (62%) | 9 (56%) | 19 (51%) |
 tender | 116 (81.1%) | 25 (68%) | 21 (62%) | 9 (56%) | 21 (57%) |
 LOM | 121 (84.6%) | 25 (68%) | 27 (79%) | 8 (50%) | 23 (62%) |
 active | 120 (83.9%) | 24 (65%) | 25 (74%) | 9 (56%) | 22 (59%) |
 number of active joints mean +/-SD | 9.0 +/- 11.2 | 5.1 +/- 8.5 | 5.6 +/- 8.4 | 2.3 +/- 2.3 | 3.2 +/- 4.8 |
 median (IQR) | 4.0 (2.0; 11.0) | 3.0 (0.0; 6.0) | 3.0 (0.3; 7.5) | 2.5 (0.0; 4.3) | 1.0 (0.0; 4.0) |
ESR >20Â mm/1Â h | 107/135 (79.3%) | 21 (66%) | 12 (55%) | 4/8 (50%) | 16/31 (52%) |
CRP >6Â mg/l | 113/137 (82.5%) | 26 (79%) | 18 (64%) | 11/15 (73%) | 20/34 (59%) |
JADAS-10 mean +/- SD (0–14)] | 20.7 +/- 9.1 | 18.8 +/- 10.4 | 14.2 +/- 10.5 | 14.2 +/- 9.7 | 13.0 +/- 9.8 |
JADAS-10 CRP mean +/- (0–40) | 22.2 +/- 9.8 | 22.3 +/- 11.2 | 15.3 +/- 9.9 | 4.3 +/- 10.2 | 13.4 +/- 10.6 |